Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Other drugs, including Novo Nordisk's GLP-1 agonist semaglutide, are also in late-stage development for the disease. "Testing new MASH treatments often relies on liver biopsies, where small pieces ...

Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a ...

Innovent announces phase 3 study of mazdutide in Chinese adults with overweight or obesity (GLORY-1) published in the NEJM: San Francisco, US Tuesday, May 27, 2025, 11:00 Hrs [IST ...

Other GLP-1-targeting drugs for obesity and diabetes are also being explored for their potential in MASH – including Novo Nordisk’s Ozempic/Wegovy (semaglutide) and Eli Lilly’s Mounjaro ...

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...